We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

Clinical Approaches and Outcomes of Serous Endometrial Cancer in a Large Tertiary Referral Centre

Submitted

19 Views
0 Downloads
0 Saves

Presented at

ESGO State of the Art 2018 Conference

-

Presentation

thumbnail

Abstract

Clinical Approaches and Outcomes of Serous Endometrial Cancer in a Large Tertiary Referral Centre Background Currently there is a lack of consensus on the uniform management of Serous Endometrial cancer, owing to the fact that often these patients are poor surgical and oncology candidates. Aims To describe the clinical approach and outcomes of 57 patients with Serous Endometrial cancer in a larger tertiary referral centre. Methods A retrospective study from January 2009 to January 2018 of all cases of predominantly serous histology. Data parameters including treatment regimens and survival patterns were recorded. Results A total of 57 patients with an average age at presentation of 67.5 years (47-92) were included in the study. Upon diagnosis, 9/57 (16%) had an ASA 3 and were deemed un-suitable for surgical intervention. 5/9 (55.5%) received neoadjuvant chemotherapy, 2/9 (22.2%) received palliative RT while 2/9 (22.2%) declined treatment. 48/57 (84.2%) had upfront de-bulking surgery with a wide variation in the choice of adjuvant therapy; Chemo+RT 18/48 (37.5%), Chemo Only 16/48 (33.3%), RT only 3/48 (6.2%), Progesterone only 2/48 (4.1%), No Therapy 9/48 (5.9%). The 18 month progression free survival was 51.1%. There was a statistically significant difference in the 18 month progression free survival between the Chemo+RT and the Chemo only group; (71% V 42%: P<0.05). Conclusion A larger percentage of these patients receive neoadjuvant treatment only compared to their Endometrioid counterparts. There is a wide variation in adjuvant treatments with those receiving combined chemotherapy and radiotherapy having higher progression free survivals at 18 months.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.